MICHELLE PAYNE: Open Payments
NPI 1487025300 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,991 in 59 payments from 14 companies in 2025. Trend: 2023 $665 · 2024 $1,785 · 2025 $1,991
Food & beverage: $1,935Education: $56
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $503 |
| Regeneron Healthcare Solutions, Inc. | 12 | $478 |
| GlaxoSmithKline, LLC. | 15 | $411 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $252 |
| GENZYME CORPORATION | 3 | $93 |
| Amgen Inc. | 2 | $51 |
| Novartis Pharmaceuticals Corporation | 2 | $48 |
| CSL Behring | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $23 |
Products named: DUPIXENT, NUCALA, NEFFY, TEZSPIRE, FASENRA, AIRSUPRA, TRELEGY ELLIPTA, Andembry.
Industry payments across AL — which companies pay providers there.
